亚辉龙与深圳技术大学合作的"智能诊断与精准医疗联合实验室"将聚焦智能诊断与精准医疗两大方向， 重点开展AI图像识别系统研发、微流控检测平台搭建、外泌体等新型生物标志物挖掘、中药及功能性 食品资源开发等关键技术攻关。深圳技术大学健康与环境工程学院在智能算法、微流控技术上积累深 厚，与亚辉龙的产业转化与市场经验形成强互补。合作双方计划在3至5年内推动一批核心研发成果向市 场化产品转化，并同步培养具备创新能力和工程实践能力的复合型人才，致力于建设成为粤港澳大湾区 智能诊断与精准医疗领域的技术策源地和人才高地。 在一天之内连续与两所高校达成实质性合作，亚辉龙展现出在生命健康领域加速布局的决心与执行力。 两家联合实验室虽聚焦方向不同，但都体现了亚辉龙以"临床需求为导向、产业转化为目标"的合作逻 辑。 亚辉龙董事长兼CEO胡鹍辉在两次活动中均强调，企业与高校的合作不仅是项目对接，更是系统化、制 度化的长期协作。通过联合实验室这一载体，亚辉龙希望实现"前沿研究—技术开发—产品转化—临床 应用"的全链条打通，真正推动科技成果造福患者。 1月19日，亚辉龙分别与香港中文大学(深圳)、深圳技术大学签署协议，正式揭牌成立"神经诊疗 ...

Core Insights - Shenzhen YHLO Biotech Co., Ltd. has made significant strides in the field of industry-academia-research collaboration by establishing two joint laboratories with Hong Kong University of Science and Technology (Shenzhen) and Shenzhen Technology University, focusing on neurological diagnosis and intelligent diagnostics [2][3] Group 1: Joint Laboratories - The "Neurodiagnosis Joint Laboratory" will focus on major neurodegenerative diseases such as Alzheimer's and Parkinson's, conducting systematic research on disease biomarkers, diagnostic technology development, and key equipment research [3] - The "Intelligent Diagnosis and Precision Medicine Joint Laboratory" will concentrate on AI image recognition systems, microfluidic detection platforms, and the exploration of new biomarkers, aiming to develop key technologies in intelligent diagnostics and precision medicine [3] Group 2: Strategic Goals - Both laboratories aim to convert core research outcomes into marketable products within 3 to 5 years while cultivating innovative and practical talent [3] - The establishment of these laboratories reflects YHLO's commitment to a clinical demand-oriented and industry transformation-focused collaboration logic [3][4] Group 3: Long-term Collaboration - YHLO's Chairman and CEO emphasized that the collaboration with universities is not just about project alignment but also about systematic and institutional long-term cooperation [4] - The joint laboratories are expected to facilitate a full chain from frontier research to technology development, product transformation, and clinical application, ultimately benefiting patients [4][5]

1月19日，亚辉龙分别与香港中文大学(深圳)、深圳技术大学签署协议，正式揭牌成立"神经诊疗联合实 验室"与"智能诊断与精准医疗联合实验室"。两家联合实验室同日启动，标志着亚辉龙在神经疾病诊 疗、智能诊断与精准医疗两大前沿方向同步深化布局，进一步巩固其在体外诊断与生命健康领域的技术 整合与产业转化能力。 据悉，港中大(深圳)—亚辉龙神经诊疗联合实验室将重点围绕阿尔茨海默症、帕金森病等重大神经退行 性疾病，开展疾病标志物发现、诊断技术构建、关键设备研发等系统性研究。未来将整合高校在神经科 学基础研究方面的优势，与企业产业化能力相结合，重点攻关神经精神疾病相关蛋白研究、柔性可穿戴 检测设备、认知障碍评估系统、术中神经监测设备等方向，覆盖神经疾病诊断、治疗、康复全流程。 亚辉龙与深圳技术大学合作的"智能诊断与精准医疗联合实验室"将聚焦智能诊断与精准医疗两大方向， 重点开展AI图像识别系统研发、微流控检测平台搭建、外泌体等新型生物标志物挖掘、中药及功能性 食品资源开发等关键技术攻关。深圳技术大学健康与环境工程学院在智能算法、微流控技术上积累深 厚，与亚辉龙的产业转化与市场经验形成强互补。合作双方计划在3至5年内推动一批 ...

Group 1 - On January 19, Shenzhen Aihuilong Biotechnology Co., Ltd. (Aihuilong, 688575.SH) established two joint laboratories with Hong Kong University of Science and Technology (Shenzhen) and Shenzhen Technology University, focusing on neurological disease diagnosis and intelligent diagnosis and precision medicine [1][2] - The "Neurodiagnosis Joint Laboratory" will focus on early diagnosis and treatment of neurological diseases, particularly Alzheimer's and Parkinson's diseases, addressing the challenges in the diagnosis of neurological disorders [4][8] - The "Intelligent Diagnosis and Precision Medicine Joint Laboratory" aims to develop AI image recognition systems, microfluidic detection platforms, and new biomarkers, leveraging the strengths of both universities and Aihuilong's market experience [5][7] Group 2 - Aihuilong's collaboration with two universities reflects its commitment to integrating clinical needs with industrial transformation, emphasizing a systematic and long-term partnership approach [8] - The establishment of these laboratories is expected to enhance Aihuilong's product line and technical reserves, contributing to the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area [8] - The joint laboratories will facilitate a comprehensive approach from cutting-edge research to clinical application, aiming to create an innovative ecosystem in the health industry [8]

截至2026年1月16日收盘，亚辉龙(688575)报收于15.15元，下跌1.5%，换手率1.33%，成交量7.59万手， 成交额1.15亿元。 当日关注点 交易信息汇总 资金流向 公司公告汇总 关于开展外汇套期保值业务的公告 深圳市亚辉龙生物科技股份有限公司及其子公司拟开展外汇套期保值业务，资金额度不超过人民币 60,000万元或等值外币，预计动用的交易保证金和权利金上限为3,000万元或等值外币，资金来源为自有 资金。业务有效期为董事会审议通过之日起12个月内，额度内资金可循环使用。公司已召开第四届董事 会第九次会议审议通过该事项，无需提交股东大会审议。业务以规避和防范汇率风险为目的，不进行投 机和套利交易。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月16日主力资金净流出1779.14万元，显示主力短期谨慎态度。 来自公司公告汇总：亚辉龙拟开展外汇套期保值业务，额度不超过人民币6亿元，旨在规避汇率风 险。 1月16日主力资金净流出1779.14万元；游资资金净流入1560.78万元；散户资金净流入2 ...

Core Viewpoint - The recent surge in A-share market activity has led to regulatory scrutiny of several companies involved in popular concepts like commercial aerospace, brain-computer interfaces, and artificial intelligence due to issues with information disclosure and risk warnings [1][2]. Group 1: Companies Under Scrutiny - Five companies, including Hangxiao Steel Structure, Electric Science Digital, Yahui Long, Yingjixin, and Tianpu Co., have received warning letters or are under investigation for misleading disclosures related to trending market concepts [1][2]. - Tianpu Co. experienced a significant stock price increase of 16 times by 2025, raising concerns about its information disclosure practices [1]. Group 2: Specific Company Issues - Hangxiao Steel Structure failed to accurately disclose the impact of its involvement in a commercial aerospace project, with the contract amount accounting for less than 1% of its 2024 audited revenue [2]. - Electric Science Digital reported that its satellite communication and AI products had minimal sales impact, with 2025 orders amounting to approximately 0.1% of overall business [3]. - Yahui Long's announcement regarding a strategic partnership in brain-computer interfaces lacked clarity on the technical capabilities of its partner, leading to regulatory warnings [4][5]. - Yingjixin's disclosures about its brain-computer interface chip were found to be misleading regarding the product's market readiness and sales impact [6]. - Tianpu Co. did not clarify its connection to artificial intelligence despite establishing a subsidiary focused on related technologies, leading to regulatory action [7][8]. Group 3: Historical Context and Trends - Several of the companies involved have a history of information disclosure issues, with Hangxiao Steel Structure being notably linked to a major insider trading case [12][13]. - The information disclosure ratings of these companies have declined significantly, with Hangxiao Steel Structure dropping from B to C, Electric Science Digital from A to B, and Tianpu Co. from B to D [12].

Core Viewpoint - Aihuilong (688575) has experienced a decline in stock price, closing at 15.15 yuan, down 3.13% from the previous week, with a total market capitalization of 8.657 billion yuan [1] Company Announcements - Aihuilong plans to engage in foreign exchange hedging activities with a limit not exceeding 600 million yuan or equivalent foreign currency, aimed at mitigating exchange rate risks [1] - The expected maximum transaction margin and premium for this hedging activity is set at 30 million yuan or equivalent foreign currency, funded by the company's own resources [1] - The business will be valid for 12 months from the date of approval by the board of directors and the funds within the limit can be reused [1] - The board of directors has approved this matter in its ninth meeting of the fourth session, and it does not require submission to the shareholders' meeting for approval [1]

Core Viewpoint - Shenzhen Yahui Long Biotechnology Co., Ltd. plans to conduct foreign exchange hedging business with a maximum amount of RMB 600 million or equivalent foreign currency to mitigate exchange rate risks [2][3]. Group 1: Overview of Foreign Exchange Hedging Business - The purpose of the foreign exchange hedging business is to manage exchange rate and interest rate risks arising from the company's import and export operations, primarily involving foreign currency settlements [3]. - The hedging activities will be based on normal production and operations, aiming to avoid speculative and arbitrage trading [3][4]. Group 2: Transaction Amount and Funding - The company intends to use no more than RMB 600 million or equivalent foreign currency from its own funds for the hedging activities, with a maximum of RMB 30 million or equivalent foreign currency allocated for transaction margins and premiums [2][4]. - The funding will come from the company's own resources and will not involve raised funds [5]. Group 3: Transaction Methods and Approval - The hedging tools may include forward foreign exchange contracts, foreign exchange swaps, foreign exchange options, foreign exchange interest rate swaps, foreign exchange futures, and currency swaps [5]. - The board of directors approved the hedging proposal on January 15, 2026, and this matter does not require submission to the shareholders' meeting [8]. Group 4: Risk Analysis - The foreign exchange hedging business aims to effectively manage foreign currency assets and mitigate risks from exchange rate fluctuations, although it still carries certain risks such as market risk, credit risk, and liquidity risk [9][10]. - The company will not engage in speculative trading, focusing instead on risk management [11]. Group 5: Impact on the Company and Accounting Treatment - The foreign exchange hedging activities are intended to mitigate risks from exchange rate fluctuations, and related hedging instruments will be treated as trading financial assets/liabilities according to accounting standards [13].

Core Viewpoint - The company, Aihuilong (688575), has announced plans to engage in foreign exchange hedging activities to mitigate currency risk, with a funding limit of up to 600 million RMB or equivalent foreign currency [1] Group 1: Stock Performance - As of January 16, 2026, Aihuilong's stock closed at 15.15 RMB, down 1.5% from the previous trading day [1] - The stock opened at 15.39 RMB, reached a high of 15.53 RMB, and a low of 15.00 RMB, with a trading volume of 1.15 billion RMB and a turnover rate of 1.33% [1] Group 2: Business Announcement - Aihuilong and its subsidiaries plan to conduct foreign exchange hedging with a maximum funding limit of 600 million RMB or equivalent foreign currency [1] - The expected maximum margin and premium for the transactions will be 30 million RMB or equivalent foreign currency, funded from the company's own resources [1] - The business will be valid for 12 months from the date of approval by the board of directors and the funds within the limit can be reused [1] - The board has approved this matter in its ninth meeting, and it does not require submission to the shareholders' meeting [1] - The purpose of this business is to avoid and prevent exchange rate risks, without engaging in speculation or arbitrage [1]

证券代码：688575 证券简称：亚辉龙 公告编号：2026-005 深圳市亚辉龙生物科技股份有限公司 关于开展外汇套期保值业务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"或"亚辉龙"）及 其子公司拟进行外汇套期保值业务资金额度不超过人民币60,000万元或等值外 币，预计动用的交易保证金和权利金上限（包括为交易而提供的担保物价值、预 计占用的金融机构授信额度、为应急措施所预留的保证金等）为3,000万元或等 值外币。资金来源为自有资金，不涉及募集资金。上述额度有效期为自公司董事 会审议通过之日起12个月内，在上述额度范围内，资金可循环滚动使用。 公司的套期保值业务以正常生产经营为基础，以规避和防范汇率风险为 目的，不进行单纯以营利为目的的投机和套利交易。 公司于2026年1月15日召开了第四届董事会第九次会议，审议通过了《关 于开展外汇套期保值业务的议案》，本次外汇套期保值业务事项无需提交公司股 东大会审议。 特别风险提示：公司开展外汇套期保值 ...